OXFORD , England , May 18 / PRNewswire / -- PharmaVentures Ltd , announced today that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic , Kappaproct ( DIMS 0150 ) , for the treatment of steroid resistant / dependent Inflammatory Bowel Disease ( IBD ) .